cAMPfield Therapeutics is a newly formed biotechnology company backed by Mountainfield Venture Partners and other life-science investors to advance licensed development-stage therapeutic candidates. Its CEO, Bill Gerhart, has more than two decades of experience in pulmonary, fibrosis, and inflammatory diseases and a track record of leading biotech exits. Other senior leaders include CTO Patricia Turney and global head of regulatory affairs Rita Shah. Public filings and reporting link cAMPfield to vTv Therapeutics' HPP737, a PDE4 inhibitor that has been studied in China for psoriasis, COPD, atopic dermatitis, and idiopathic pulmonary fibrosis, including an ongoing Phase 3 psoriasis trial there. The company's explicit pipeline needs are not detailed in the coverage, nor are financial metrics beyond the $180 million Series A. cAMPfield appears positioned to progress licensed candidates through clinical development with capital from its recent financing.

Total raised

$180M

Funding rounds

1

Latest round

Series A

Latest activity

May 2026